R-CHOP regimen: Difference between revisions

Jump to navigation Jump to search
mNo edit summary
mNo edit summary
Line 6: Line 6:


==Overview==
==Overview==
{{PAGENAME}} refers to an immunochemotherapy regimen consisting of [[rituximab]], [[cyclophosphamide]], [[doxorubicin |hydroxydaunorubicin hydrochloride (doxorubicin hydrochloride)]], [[vincristine|vincristine (Oncovin)]] and [[prednisone]] used to treat both indolent and aggressive forms of [[non-Hodgkin lymphoma]].<ref>{{Cite web | title = NCI Thesaurus | accessdate =  | url = http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C63452 }}</ref><ref>{{Cite web | title = R-CHOP - National Cancer Institute | accessdate = 2015-02-20 | url = http://www.cancer.gov/cancertopics/druginfo/R-CHOP }}</ref>
{{PAGENAME}} refers to an immunochemotherapy regimen consisting of [[rituximab]], [[cyclophosphamide]], [[doxorubicin |hydroxydaunorubicin hydrochloride (doxorubicin hydrochloride)]], [[vincristine|vincristine (Oncovin)]] and [[prednisone]] used to treat both indolent and aggressive forms of [[non-Hodgkin lymphoma]].<ref>{{Cite web | title = NCI Thesaurus | accessdate =  | url = http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C63452 }}</ref><ref>{{Cite web | title = R-CHOP - National Cancer Institute | accessdate = | url = http://www.cancer.gov/cancertopics/druginfo/R-CHOP }}</ref>


==Regimen==
==Regimen==

Revision as of 16:12, 20 February 2015

WikiDoc Resources for R-CHOP regimen

Articles

Most recent articles on R-CHOP regimen

Most cited articles on R-CHOP regimen

Review articles on R-CHOP regimen

Articles on R-CHOP regimen in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on R-CHOP regimen

Images of R-CHOP regimen

Photos of R-CHOP regimen

Podcasts & MP3s on R-CHOP regimen

Videos on R-CHOP regimen

Evidence Based Medicine

Cochrane Collaboration on R-CHOP regimen

Bandolier on R-CHOP regimen

TRIP on R-CHOP regimen

Clinical Trials

Ongoing Trials on R-CHOP regimen at Clinical Trials.gov

Trial results on R-CHOP regimen

Clinical Trials on R-CHOP regimen at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on R-CHOP regimen

NICE Guidance on R-CHOP regimen

NHS PRODIGY Guidance

FDA on R-CHOP regimen

CDC on R-CHOP regimen

Books

Books on R-CHOP regimen

News

R-CHOP regimen in the news

Be alerted to news on R-CHOP regimen

News trends on R-CHOP regimen

Commentary

Blogs on R-CHOP regimen

Definitions

Definitions of R-CHOP regimen

Patient Resources / Community

Patient resources on R-CHOP regimen

Discussion groups on R-CHOP regimen

Patient Handouts on R-CHOP regimen

Directions to Hospitals Treating R-CHOP regimen

Risk calculators and risk factors for R-CHOP regimen

Healthcare Provider Resources

Symptoms of R-CHOP regimen

Causes & Risk Factors for R-CHOP regimen

Diagnostic studies for R-CHOP regimen

Treatment of R-CHOP regimen

Continuing Medical Education (CME)

CME Programs on R-CHOP regimen

International

R-CHOP regimen en Espanol

R-CHOP regimen en Francais

Business

R-CHOP regimen in the Marketplace

Patents on R-CHOP regimen

Experimental / Informatics

List of terms related to R-CHOP regimen

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]

Synonyms and keywords: Rituximab-Cyclophosphamide-Hydroxydaunorubicin-Oncovin-Prednisone regimen

Overview

R-CHOP regimen refers to an immunochemotherapy regimen consisting of rituximab, cyclophosphamide, hydroxydaunorubicin hydrochloride (doxorubicin hydrochloride), vincristine (Oncovin) and prednisone used to treat both indolent and aggressive forms of non-Hodgkin lymphoma.[1][2]

Regimen

R – Rituximab

C – Cyclophosphamide

H – Doxorubicin (Hydroxydaunomycin)

O – Vincristine (Oncovin)

P – Prednisone

Indications

See also

References

  1. "NCI Thesaurus".
  2. "R-CHOP - National Cancer Institute".
  3. Coiffier, Bertrand (2002-01-24). "CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma". The New England Journal of Medicine. 346 (4): 235–242. doi:10.1056/NEJMoa011795. ISSN 1533-4406. PMID 11807147. Unknown parameter |coauthors= ignored (help)